Ana Debarros

Ana Debarros

Auto-generated profile, based on publicly available information

Ana Debarros

Unidade de Imunologia Molecular, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa , 1649-028 Lisboa

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2009 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
JRJulie C Ribot
Julie C Ribot
ADAna Debarros
Ana Debarros
DPDick John Pang
Dick John Pang
JNJoana F Neves
Joana F Neves
VPVictor Peperzak
Victor Peperzak
BSBruno Silva-Santos
Bruno Silva-Santos

27 October 2010 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
ADAna Debarros
Ana Debarros
MCMiguel Chaves‐Ferreira
Miguel Chaves‐Ferreira
FDFrancisco D'Orey
Francisco D'Orey
JRJulie C. Ribot
Julie C. Ribot
BSBruno Silva‐Santos
Bruno Silva‐Santos
Human Vγ9Vδ2 T cells are potent anti‐tumor lymphocytes that specifically respond to pyrophosphate (phospho‐) antigens, which constitute the basis of current γδ T‐cell‐based immunotherapy strategies. Despite a clear involvement of the TCR, the costimulation requirements of Vγ9Vδ2 T cells remain ill‐defined. Here, we show that the expression of the CD27 receptor by the vast majority of Vγ9Vδ2 peripheral blood lymphocytes endows them with enhanced proliferative capacity upon ligation by its unique ligand CD70, a tumor necrosis factor superfamily member expressed on lymphoma B‐cells but also on TCR‐activated γδ T cells. Moreover, Vγ9Vδ2 T‐cell treatment with soluble recombinant CD70 induced calcium signals and increased transcription of anti‐apoptotic Bcl2a1 and cell‐cycle‐promoting Cyclin D2 genes. We further demonstrate that the manipulation of CD70–CD27 interactions significantly impacted on Vγ9Vδ2 T‐cell survival, proliferation and cytokine secretion, in both loss‐of‐function and gain‐of‐function experiments. Thus, CD27 coreceptor signals strongly promoted the expansion of Th1‐biased, CD27+ Vγ9Vδ2 peripheral blood lymphocytes in the context of TCR‐mediated stimulation with phosphoantigens. These data collectively establish a novel role for the CD70–CD27 axis in human γδ T‐cell activation and hence open new perspectives for its modulation in clinical settings.

1 August 2012 in The Journal of Immunology
Verified
Journal Article
Closed access
JRJulie C Ribot
Julie C Ribot
ADAna Debarros
Ana Debarros
LMLiliana Mancio-Silva
Liliana Mancio-Silva
APAna Pamplona
Ana Pamplona
BSBruno Silva-Santos
Bruno Silva-Santos
γδ T cells play key nonredundant roles in immunity to infections and tumors. Thus, it is critical to understand the molecular mechanisms responsible for γδ T cell activation and expansion in vivo. In striking contrast to their αβ counterparts, the costimulation requirements of γδ T cells remain poorly understood. Having previously described a role for the TNFR superfamily member CD27, we since screened for other nonredundant costimulatory receptors in γδ T cell activation. We report in this article that the Ig superfamily receptor CD28 (but not its related protein ICOS) is expressed on freshly isolated lymphoid γδ T cells and synergizes with the TCR to induce autocrine IL-2 production that promotes γδ cell survival and proliferation in both mice and humans. Specific gain-of-function and loss-of-function experiments demonstrated a nonredundant function for CD28 interactions with its B7 ligands, B7.1 (CD80) and B7.2 (CD86), both in vitro and in vivo. Thus, γδ cell proliferation was significantly enhanced by CD28 receptor agonists but abrogated by B7 Ab-mediated blockade. Furthermore, γδ cell expansion following Plasmodium infection was severely impaired in mice genetically deficient for CD28. This resulted in the failure to mount both IFN-γ–mediated and IL-17–mediated γδ cell responses, which contrasted with the selective effect of CD27 on IFN-γ–producing γδ cells. Our data collectively show that CD28 signals are required for IL-2–mediated survival and proliferation of both CD27+ and CD27− γδ T cell subsets, thus providing new mechanistic insight for their modulation in disease models.

4 May 2011 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
JRJulie C. Ribot
Julie C. Ribot
ADAna Debarros
Ana Debarros
BSBruno Silva-Santos
Bruno Silva-Santos

21 May 2009 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DCDaniel V. Correia
Daniel V. Correia
FDFrancisco D'ORey
Francisco D'ORey
BCBruno António Cardoso
Bruno António Cardoso
TLTelma Lança
Telma Lança
AGAna Rita Grosso
Ana Rita Grosso
BSBruno Silva-Santos
Bruno Silva-Santos
The unique responsiveness of Vγ9Vδ2 T-cells, the major γδ subset of human peripheral blood, to non-peptidic prenyl pyrophosphate antigens constitutes the basis of current γδ T-cell-based cancer immunotherapy strategies. However, the molecular mechanisms responsible for phosphoantigen-mediated activation of human γδ T-cells remain unclear. In particular, previous reports have described a very slow kinetics of activation of T-cell receptor (TCR)-associated signal transduction pathways by isopentenyl pyrophosphate and bromohydrin pyrophosphate, seemingly incompatible with direct binding of these antigens to the Vγ9Vδ2 TCR. Here we have studied the most potent natural phosphoantigen yet identified, (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-PP), produced by Eubacteria and Protozoa, and examined its γδ T-cell activation and anti-tumor properties. We have performed a comparative study between HMB-PP and the anti-CD3ε monoclonal antibody OKT3, used as a reference inducer of bona fide TCR signaling, and followed multiple cellular and molecular γδ T-cell activation events. We show that HMB-PP activates MEK/Erk and PI-3K/Akt pathways as rapidly as OKT3, and induces an almost identical transcriptional profile in Vγ9+ T-cells. Moreover, MEK/Erk and PI-3K/Akt activities are indispensable for the cellular effects of HMB-PP, including γδ T-cell activation, proliferation and anti-tumor cytotoxicity, which are also abolished upon antibody blockade of the Vγ9+ TCR Surprisingly, HMB-PP treatment does not induce down-modulation of surface TCR levels, and thereby sustains γδ T-cell activation upon re-stimulation. This ultimately translates in potent human γδ T-cell anti-tumor function both in vitro and in vivo upon transplantation of human leukemia cells into lymphopenic mice, The development of efficient cancer immunotherapy strategies critically depends on our capacity to maximize anti-tumor effector T-cell responses. By characterizing the intracellular mechanisms of HMB-PP-mediated activation of the highly cytotoxic Vγ9+ T-cell subset, our data strongly support the usage of this microbial antigen in novel cancer clinical trials.

30 December 2009 in European Journal of Immunology
Verified
Journal Article
Closed access
PDF file
NGNatacha Gonçalves‐Sousa
Natacha Gonçalves‐Sousa
JRJulie C. Ribot
Julie C. Ribot
ADAna Debarros
Ana Debarros
DCDaniel V. Correia
Daniel V. Correia
ICIris Caramalho
Iris Caramalho
BSBruno Silva‐Santos
Bruno Silva‐Santos